vs
Side-by-side financial comparison of HARTE HANKS INC (HHS) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.
HARTE HANKS INC is the larger business by last-quarter revenue ($39.9M vs $38.3M, roughly 1.0× ImmunityBio, Inc.). HARTE HANKS INC runs the higher net margin — 5.5% vs -161.8%, a 167.3% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -15.4%). HARTE HANKS INC produced more free cash flow last quarter ($-686.0K vs $-71.3M).
Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
HHS vs IBRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $39.9M | $38.3M |
| Net Profit | $2.2M | $-61.9M |
| Gross Margin | — | 99.0% |
| Operating Margin | -0.3% | -169.0% |
| Net Margin | 5.5% | -161.8% |
| Revenue YoY | -15.4% | 407.0% |
| Net Profit YoY | — | -4.7% |
| EPS (diluted) | $0.30 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $39.9M | $38.3M | ||
| Q3 25 | $39.5M | $32.1M | ||
| Q2 25 | $38.6M | $26.4M | ||
| Q1 25 | $41.6M | $16.5M | ||
| Q4 24 | $47.1M | $7.6M | ||
| Q3 24 | $47.6M | $6.1M | ||
| Q2 24 | $45.0M | — | ||
| Q1 24 | $45.4M | — |
| Q4 25 | $2.2M | $-61.9M | ||
| Q3 25 | $-2.3M | $-67.3M | ||
| Q2 25 | $-335.0K | $-92.6M | ||
| Q1 25 | $-392.0K | $-129.6M | ||
| Q4 24 | — | $-59.2M | ||
| Q3 24 | $142.0K | $-85.7M | ||
| Q2 24 | $-27.8M | — | ||
| Q1 24 | $-171.0K | — |
| Q4 25 | — | 99.0% | ||
| Q3 25 | — | 99.4% | ||
| Q2 25 | — | 99.5% | ||
| Q1 25 | — | 99.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -0.3% | -169.0% | ||
| Q3 25 | 1.3% | -173.5% | ||
| Q2 25 | 0.1% | -269.8% | ||
| Q1 25 | -0.1% | -390.1% | ||
| Q4 24 | -3.3% | -919.0% | ||
| Q3 24 | 4.0% | -1314.3% | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | 5.5% | -161.8% | ||
| Q3 25 | -5.8% | -209.8% | ||
| Q2 25 | -0.9% | -350.3% | ||
| Q1 25 | -0.9% | -784.9% | ||
| Q4 24 | — | -783.4% | ||
| Q3 24 | 0.3% | -1404.0% | ||
| Q2 24 | -61.8% | — | ||
| Q1 24 | -0.4% | — |
| Q4 25 | $0.30 | $-0.06 | ||
| Q3 25 | $-0.31 | $-0.07 | ||
| Q2 25 | $-0.05 | $-0.10 | ||
| Q1 25 | $-0.05 | $-0.15 | ||
| Q4 24 | $-0.31 | $-0.08 | ||
| Q3 24 | $0.02 | $-0.14 | ||
| Q2 24 | $-3.84 | — | ||
| Q1 24 | $-0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.6M | $242.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $20.5M | $-500.5M |
| Total Assets | $91.8M | $501.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.6M | $242.8M | ||
| Q3 25 | $6.5M | $257.8M | ||
| Q2 25 | $4.8M | $153.7M | ||
| Q1 25 | $9.0M | $61.6M | ||
| Q4 24 | $9.8M | $149.8M | ||
| Q3 24 | $5.9M | $130.4M | ||
| Q2 24 | $11.0M | — | ||
| Q1 24 | $11.5M | — |
| Q4 25 | $20.5M | $-500.5M | ||
| Q3 25 | $19.9M | $-524.3M | ||
| Q2 25 | $22.2M | $-570.7M | ||
| Q1 25 | $21.4M | $-591.4M | ||
| Q4 24 | $21.7M | $-489.1M | ||
| Q3 24 | $21.0M | $-745.1M | ||
| Q2 24 | $20.6M | — | ||
| Q1 24 | $20.0M | — |
| Q4 25 | $91.8M | $501.9M | ||
| Q3 25 | $92.7M | $519.0M | ||
| Q2 25 | $95.0M | $402.1M | ||
| Q1 25 | $100.6M | $303.8M | ||
| Q4 24 | $101.8M | $382.9M | ||
| Q3 24 | $108.1M | $364.6M | ||
| Q2 24 | $109.7M | — | ||
| Q1 24 | $113.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $737.0K | $-70.4M |
| Free Cash FlowOCF − Capex | $-686.0K | $-71.3M |
| FCF MarginFCF / Revenue | -1.7% | -186.2% |
| Capex IntensityCapex / Revenue | 3.6% | 2.4% |
| Cash ConversionOCF / Net Profit | 0.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-4.5M | $-308.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $737.0K | $-70.4M | ||
| Q3 25 | $3.2M | $-68.9M | ||
| Q2 25 | $-4.8M | $-79.7M | ||
| Q1 25 | $-818.0K | $-85.9M | ||
| Q4 24 | $4.0M | $-85.1M | ||
| Q3 24 | $-2.9M | $-98.8M | ||
| Q2 24 | $1.6M | — | ||
| Q1 24 | $-5.7M | — |
| Q4 25 | $-686.0K | $-71.3M | ||
| Q3 25 | $2.2M | $-69.6M | ||
| Q2 25 | $-5.1M | $-80.8M | ||
| Q1 25 | $-923.0K | $-87.0M | ||
| Q4 24 | $3.4M | $-87.3M | ||
| Q3 24 | $-4.9M | $-101.6M | ||
| Q2 24 | $926.0K | — | ||
| Q1 24 | $-6.2M | — |
| Q4 25 | -1.7% | -186.2% | ||
| Q3 25 | 5.5% | -217.2% | ||
| Q2 25 | -13.1% | -305.9% | ||
| Q1 25 | -2.2% | -526.9% | ||
| Q4 24 | 7.3% | -1155.4% | ||
| Q3 24 | -10.2% | -1663.2% | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | -13.7% | — |
| Q4 25 | 3.6% | 2.4% | ||
| Q3 25 | 2.5% | 2.3% | ||
| Q2 25 | 0.6% | 4.1% | ||
| Q1 25 | 0.3% | 6.8% | ||
| Q4 24 | 1.3% | 28.0% | ||
| Q3 24 | 4.0% | 45.7% | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 1.2% | — |
| Q4 25 | 0.33× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -20.76× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HHS
| Fulfillment And Logistics Services | $17.3M | 43% |
| Customer Care | $13.7M | 34% |
| Other | $8.9M | 22% |
IBRX
Segment breakdown not available.
